Celgene, Novartis, GV and Taiho Ventures are among the backers that provided the funding for the Stanford-backed immuno-oncology company over two rounds.
US-based immuno-oncology startup Arcus Biosciences has raised $120m across two rounds from investors including internet and technology group GV and pharmaceutical firms Taiho, Novartis and Celgene, Fierce Biotech reported yesterday.
Arcus was founded in May 2015 by Terry Rosen and Juan Jaen, co-founders in 2013 of Flexus Biosciences, the immuno-oncology therapeutics developer acquired two years later by pharmaceutical company Bristol-Myers Squibb for up to $1.25bn.
Arcus raised an initial $30m from friends and family before Novartis, Celgene and venture capital…
